rs727504448
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001927.4(DES):βc.600delβ(p.Lys201ArgfsTer20) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000031 in 1,614,088 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.0000066 ( 0 hom., cov: 32)
Exomes π: 0.0000027 ( 0 hom. )
Consequence
DES
NM_001927.4 frameshift
NM_001927.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 1.53
Genes affected
DES (HGNC:2770): (desmin) This gene encodes a muscle-specific class III intermediate filament. Homopolymers of this protein form a stable intracytoplasmic filamentous network connecting myofibrils to each other and to the plasma membrane. Mutations in this gene are associated with desmin-related myopathy, a familial cardiac and skeletal myopathy (CSM), and with distal myopathies. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 2-219420115-TG-T is Pathogenic according to our data. Variant chr2-219420115-TG-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 178660.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-219420115-TG-T is described in Lovd as [Pathogenic]. Variant chr2-219420115-TG-T is described in Lovd as [Pathogenic]. Variant chr2-219420115-TG-T is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DES | NM_001927.4 | c.600del | p.Lys201ArgfsTer20 | frameshift_variant | 2/9 | ENST00000373960.4 | NP_001918.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DES | ENST00000373960.4 | c.600del | p.Lys201ArgfsTer20 | frameshift_variant | 2/9 | 1 | NM_001927.4 | ENSP00000363071 | P1 | |
DES | ENST00000477226.6 | n.74del | non_coding_transcript_exon_variant | 1/8 | 4 | |||||
DES | ENST00000492726.1 | upstream_gene_variant | 4 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152196Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
1
AN:
152196
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461892Hom.: 0 Cov.: 36 AF XY: 0.00000275 AC XY: 2AN XY: 727248
GnomAD4 exome
AF:
AC:
4
AN:
1461892
Hom.:
Cov.:
36
AF XY:
AC XY:
2
AN XY:
727248
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152196Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74356
GnomAD4 genome
AF:
AC:
1
AN:
152196
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74356
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:2Uncertain:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Desmin-related myofibrillar myopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 27, 2022 | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 178660). This premature translational stop signal has been observed in individual(s) with clinical features of autosomal recessive DES-related conditions (PMID: 23815709). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Lys201Argfs*20) in the DES gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DES are known to be pathogenic (PMID: 23575897). - |
Primary dilated cardiomyopathy;C0027868:Neuromuscular disease Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 05, 2012 | The Lys201fs variant in DES has not been previously reported in the literature b ut has been identified by our laboratory in 1 family, where it was present in tr ans with a second DES variant (nonsense) in 2 individuals with features consiste nt with a desminopathy. Each unaffected parent carried 1 of the variants, sugge stive of recessive inheritance. This frameshift variant is predicted to alter th e protein?s amino acid sequence beginning at position 201 and lead to a prematur e termination codon 20 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. The spectrum of reported DES variants includes several similar variants (nonsense, splice, frameshift; Park 2000, Sch roeder 2003, Dunand 2009, Hong 2011, Wahbi 2011). One of these variants (Dunand 2009) showed clear autosomal dominant inheritance but this could not be conclus ively established for other variants. In summary, this variant is likely to be p athogenic though studies in 1 family suggest that it may not result in disease w hen present in isolation. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, flagged submission | clinical testing | Ambry Genetics | Jun 20, 2023 | The c.600delG variant, located in coding exon 2 of the DES gene, results from a deletion of one nucleotide at nucleotide position 600, causing a translational frameshift with a predicted alternate stop codon (p.K201Rfs*20). This alteration has been detected in trans with another truncating DES variant in siblings with profound, childhood-onset skeletal myopathy, respiratory dysfunction, and dilated cardiomyopathy (McLaughlin HM et al. BMC Med Genet, 2013 Jul;14:68). Although biallelic loss of function alterations in DES have been associated with autosomal recessive DES-related myofibrillar myopathy, haploinsufficiency for DES has not been clearly established as a mechanism of disease for autosomal dominant DES-related myopathy. Based on the supporting evidence, this variant is expected to be causative of autosomal recessive DES-related myofibrillar myopathy when present along with a second pathogenic variant on the other allele; however, its clinical significance for autosomal dominant DES-related myopathy is unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at